NMOSD and MOG Antibody Disorder Treatment Approaches

Diagnostic Considerations

NMOSD typically presents with more severe optic neuritis and longitudinally extensive transverse myelitis affecting ≥3 vertebral segments, as noted by the Brain journal in 2019 1
MRI findings can help differentiate NMOSD from MOG antibody disorder, with NMOSD showing "cloud-like" enhancement and area postrema lesions, as reported in the Brain journal in 2019 1

High-dose intravenous methylprednisolone (1-1.6 mg/kg/day) is the first-line treatment for NMOSD, according to the World of Neurosurgery journal in 2023 2, 3
Plasmapheresis is often necessary for steroid-refractory NMOSD cases, with studies showing 79.2% of patients experiencing clinical improvement, as reported in the World of Neurosurgery journal in 2023 2, 3
Early and aggressive treatment of acute NMOSD attacks is critical to prevent permanent disability, as noted by the World of Neurosurgery journal in 2023 3

Rituximab decreases relapse rates more effectively than azathioprine in head-to-head comparisons for NMOSD, according to the World of Neurosurgery journal in 2023 3
Newer targeted therapies, including eculizumab, satralizumab, and inebilizumab, have shown efficacy in reducing relapse rates for NMOSD, as reported in the World of Neurosurgery journal in 2023 3

For NMOSD, autologous hematopoietic stem cell transplantation (AHSCT) has limited evidence with mixed outcomes, with a retrospective study showing 81% of patients experienced relapse after AHSCT, as noted by Nature Reviews Neurology in 2025 4, 5
AHSCT is generally not recommended for NMOSD outside clinical trials due to the availability of highly effective pharmacological treatments, as reported by Nature Reviews Neurology in 2025 4, 6
Clearance of AQP4 antibodies appears to be a biomarker of treatment response in NMOSD, according to Nature Reviews Neurology in 2025 5

In NMOSD, monitoring AQP4 antibody levels may help assess treatment efficacy, with antibody clearance associated with durable disease remission, as reported by Nature Reviews Neurology in 2025 5
Regular clinical assessment and MRI monitoring are essential to detect early signs of relapse for both NMOSD and MOG antibody disorder, according to the World of Neurosurgery journal in 2023 3
Expanded Disability Status Scale (EDSS) scores are commonly used to monitor treatment response, with studies showing significant decreases in EDSS with appropriate therapy, as noted by the World of Neurosurgery journal in 2023 2, 3

Misdiagnosis as multiple sclerosis can lead to inappropriate treatment with MS medications that may worsen NMOSD or MOG antibody disorder, as reported by the Brain journal in 2019 1
Contraception is essential during immunosuppressive treatment periods due to teratogenic risks and potential treatment-related fertility issues, according to Nature Reviews Neurology in 2025 7

Approximately two-thirds (75%) of NMOSD patients are seropositive for AQP4-IgG antibodies, which is associated with better prognosis due to more homogeneous clinical presentation compared to seronegative patients 8
Longitudinally extensive transverse myelitis affecting three or more vertebral segments on spinal cord MRI is a clinical presentation associated with Anti-NMO positivity 9
Relapses occur in 50-60% of patients during corticosteroid dose reduction, necessitating long-term maintenance immunosuppression 9
AQP4-IgG positivity should prompt immediate initiation of disease-specific immunosuppressive therapy rather than MS-directed treatments, as some MS medications may worsen NMOSD outcomes 10
Testing should be performed using cell-based assays with full-length human MOG protein for optimal sensitivity and specificity 10
Serum testing is preferred over CSF, as serum has higher sensitivity for antibody detection 11

Between 20-50% of AQP4-IgG positive patients have concomitant autoimmune diseases 8
Antiphospholipid antibodies may co-exist and are associated with worse outcomes, including ischemic/thrombotic myelopathy requiring anticoagulation 9